Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death-
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …

The emergence and continuous development of immune checkpoint inhibitors (ICIs) therapy
brings a revolution in cancer therapy history, but the major hurdle associated with their …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small
cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can …

Purpose Consolidation immunotherapy after completion of chemoradiotherapy has become
the standard of care for unresectable locally advanced non‐small cell lung cancer and can …

Introduction PD-(L) 1 inhibitors have improved prognosis of non-small-cell lung cancer
(NSCLC), but can also cause immune-related adverse events (irAEs) that complicate …

Lung cancer is the leading cause of cancer‐related deaths worldwide. As new therapies are
developed, it is important to understand the pulmonary toxicities associated with systemic …

Background The combination of immunotherapy and chemoradiotherapy has become the
standard therapeutic strategy for patients with unresected locally advance-stage non-small …

The increasing use of immune checkpoint inhibitors in tumors has brought new hope of
survival to patients with advanced tumors. However, the immune system activated by …

Background Patients with non-small cell lung cancer may develop pneumonitis after thoracic
radiotherapy (RT) and immune checkpoint inhibitors (ICIs). We hypothesized that distinct …